Flavonoid compounds: A review of anticancer properties and interactions with cis-diamminedichloroplatinum(II)

被引:69
|
作者
Kosmider, B [1 ]
Osiecka, R [1 ]
机构
[1] Univ Lodz, Dept Cytogenet & Plant Mol Biol, PL-90237 Lodz, Poland
关键词
flavonoid compounds; cis-DDPI; anticancer properties; interactions;
D O I
10.1002/ddr.10421
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Flavonoid compounds, especially quercetin and genistein, have antitumor activity. These compounds are cytotoxic to cancer cells but have no or insignificant activity in. normal cells., These beneficial properties prompted synthesis of flavonoid synthetic derivatives, e.g., flavopiridol; 5-amino-2,3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one; B43-genistein and EGF-genistein). cis-DDP (cis-diamminedichloroplatinum(II)) is one of the most effective drugs used for chemotherapy, but its actions are limited by many side effects. Beneficial synergistic effects of flavonoids (e.g., quercetin, genistein, butein, tannic acid) and cis-DDP were found in cis-DDP-sensitive and resistant cancer cells that resulted in a lower toxicity for, cis-DDP. Further studies focused on the synthesis of complexes of compounds belonging to different groups, e.g., cis-bis(3-aminoflavone)dichloroplatinum(II) where introduction of the flavone ligand altered the DNA-binding properties of the complex as compared to cis-DDP alone. The beneficial anticancer and antioxidant properties of flavonoids and their synthetic derivatives have prompted further research on the synergistic interactions of these compounds with routinely applied chemotherapeutic drugs, e.g. cis-DDP. (c) 2004 Wiley-Liss, Inc.
引用
收藏
页码:200 / 211
页数:12
相关论文
共 50 条
  • [1] CIS-DIAMMINEDICHLOROPLATINUM(II) - NEW ANTICANCER DRUG
    ROZENCWEIG, M
    VONHOFF, DD
    SLAVIK, M
    MUGGIA, FM
    ANNALS OF INTERNAL MEDICINE, 1977, 86 (06) : 803 - 812
  • [2] MODULATION OF CIS-DIAMMINEDICHLOROPLATINUM(II) RESISTANCE - A REVIEW
    TIMMERBOSSCHA, H
    MULDER, NH
    DEVRIES, EGE
    BRITISH JOURNAL OF CANCER, 1992, 66 (02) : 227 - 238
  • [3] Molecular basis of cis-diamminedichloroplatinum(II) resistance: A review
    Chao, CCK
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1996, 95 (12) : 893 - 900
  • [4] RENAL HANDLING OF CIS-DIAMMINEDICHLOROPLATINUM(II)
    JACOBS, C
    KALMAN, SM
    TRETTON, M
    WEINER, MW
    CANCER TREATMENT REPORTS, 1980, 64 (12): : 1223 - 1226
  • [5] BINDING FOR CIS-DIAMMINEDICHLOROPLATINUM(II) TO DINUCLEOTIDES
    FORSTI, A
    LAATIKAINEN, R
    HEMMINKI, K
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (11): : 1750 - 1750
  • [6] L-Methionine inhibits reaction of DNA with anticancer cis-diamminedichloroplatinum(II)
    Vrana, O
    Brabec, V
    BIOCHEMISTRY, 2002, 41 (36) : 10994 - 10999
  • [7] Anticancer activity of alcohol amines and diaminocyclohexane derivatives of cis-diamminedichloroplatinum (II) (cisplatin).
    Dong, Y
    Narla, RK
    Uckun, FM
    CLINICAL CANCER RESEARCH, 1999, 5 : 3853S - 3854S
  • [8] Conformational and vibrational study of platinum(II) anticancer drugs:: cis-diamminedichloroplatinum(II) as a case study
    Amado, Ana M.
    Fiuza, Sonia M.
    Marques, Maria P. M.
    Batista de Carvalho, Luis A. E.
    JOURNAL OF CHEMICAL PHYSICS, 2007, 127 (18):
  • [9] CIS-DIAMMINEDICHLOROPLATINUM II IN ADVANCED UROTHELIAL CANCER
    SOLOWAY, MS
    JOURNAL OF UROLOGY, 1978, 120 (06): : 716 - 719
  • [10] STUDIES OF THE MECHANISM OF ACTION OF CIS-DIAMMINEDICHLOROPLATINUM(II)
    LIPPARD, SJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1983, 185 (MAR): : 12 - MEDI